Showing results (41-50 of 51) with videos related to
Sort By:
Pageof 6
Nature Reviews. Clinical Oncology|May 5, 2016
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combinationCeline Boutros, Ahmad Tarhini, Emilie Routier, et al.JAMA Oncology|July 17, 2020
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical TrialsIgor Puzanov, Antoni Ribas, Caroline Robert, et al.Journal for Immunotherapy of Cancer|November 16, 2021
Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanomaWalter J Storkus, Deena Maurer, Yan Lin, et al.The New England Journal of Medicine|August 23, 2018
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the BrainHussein A Tawbi, Peter A Forsyth, Alain Algazi, et al.Biorxiv : the Preprint Server for Biology|September 30, 2024
Tenascin-C in the early lung cancer tumor microenvironment promotes progression through integrin αvβ1 and FAKShiela C Samson, Anthony Rojas, Rebecca G Zitnay, et al.The Lancet. Oncology|November 14, 2021
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 studyHussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.Nature Reviews. Clinical Oncology|August 29, 2013
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanomaHoward L Kaufman, John M Kirkwood, F Stephen Hodi, et al.Journal of Translational Medicine|November 17, 2016
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015Paolo A Ascierto, Sanjiv Agarwala, Gerardo Botti, et al.Lancet (London, England)|September 15, 2022
Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trialSungjune Kim, Evan Wuthrick, Dukagjin Blakaj, et al.Research Square|June 12, 2026
The Oncology Research Information Exchange Network (ORIEN) - Building a real-world collaborative, patient-driven infrastructure for discovery research and precision oncologyMichelle Churchman, Xin Lu, David McKean, et al.Pageof 6